Correction to: Oncogene
https://doi.org/10.1038/s41388-019-0795-5 Published online 10 April 2019
In the original version of this article the authors noted a number of minor errors that required correction.
In the abstract, “β-CatSer552” should have been listed as “β-Cat Ser552”. In the introduction, “p-β-Cat S552” should have been listed as “p-β-Cat Ser552”.
The Fig. 1 legend should read as follows:
Cld-1 intensifies colitis, leads to impaired recovery from DSS induction and triggers dysplasia: a Schematic illustration of the experimental protocol. Age-matched and sex-matched WT (n = 8) and Cld-1 Tg (n = 8) mice were treated with 2.5% DSS in drinking water for 7 days ad libitum (colitis group), followed by drinking water for 10 days (DSS recovery group). b Representative histological images of WT and Cld-1 Tg mice under DSS and DSS recovery protocol showing regenerative crypts in WT DSS Recovery and dysplastic crypts in Cld-1 Tg Recovery. c The mean changes in body weight of the WT and Cld-1 Tg mice after being fed with 2.5% DSS were measured every day until day 7 for the colitis group and day 10 for the DSS recovery group. The percentage of mice possessing dysplastic crypt in the recovery protocol among WT and Cld-1 Tg groups. Results are statistically significant at p < 0.05. Values sharing following symbols differ significantly, asterisk (*) compared with WT DSS Recovery.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gowrikumar, S., Ahmad, R., Uppada, S.B. et al. Correction: Upregulated claudin-1 expression promotes colitis-associated cancer by promoting β-catenin phosphorylation and activation in Notch/p-AKT-dependent manner. Oncogene 38, 6566 (2019). https://doi.org/10.1038/s41388-019-0864-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41388-019-0864-9
This article is cited by
-
Wnt/β-catenin signaling in cancers and targeted therapies
Signal Transduction and Targeted Therapy (2021)
-
MASTL regulates EGFR signaling to impact pancreatic cancer progression
Oncogene (2021)